Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Month: April 2022
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Results from UB-312’s Part A first-in-human trials published in Movement Disorders DALLAS, April 28, 2022…
Cytek Biosciences Appoints Todd Garland Chief Commercial Officer
Industry Seasoned Executive Joins Cytek FREMONT, Calif., April 28, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences,…
Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a…
ProKidney Appoints Libbie Parker McKenzie, MD, FASN as Chief Medical Officer
WINSTON-SALEM, N.C., April 28, 2022 (GLOBE NEWSWIRE) — ProKidney LP (ProKidney), a leading clinical-stage cellular…
PROCEPT BioRobotics Corporation Announces Aetna and Independence Blue Cross Blue Shield Positive Coverage Decisions Regarding Aquablation Therapy for Men with Enlarged Prostates
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a surgical…
Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
Preclinical data demonstrates that UCART123 effectively eliminates AML with no major impact on normal hematopoietic progenitor…
New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022
Data support the continued development of OPGx-001 and OPGx-002 to address mutations in genes causing…
Virax Biolabs Announces the Appointment of Jason D. Davis as Chief Financial Officer
London, United Kingdom, April 28, 2022 (GLOBE NEWSWIRE) — Virax Biolabs Group Limited (“Virax” or…
InMed Expands Patent Portfolio with Novel Cannabinoid Analogs and Advances Collaboration Agreement with Leading Cannabinoid Research Expert
Expands library of proprietary cannabinoid analogs for pharma R&D Research collaboration initiated to screen analogs…
Avicanna Expands RHO PhytoTM Formulary with the Introduction of Cannabigerol (CBG) Products into the Canadian Market
Avicanna introduces the rare cannabinoid CBG into its RHO Phyto product formulary which includes oral,…
Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study
91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review…
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
OpGen to Provide Business Update and Financial Results for the First Quarter 2022 on May 12th at 4:30 p.m. Eastern Time
ROCKVILLE, Md., April 28, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the…
Nevakar Injectables Receives U.S. FDA Approval of Ready-to-Use Ephedrine Injection in a Prefilled Syringe
BRIDGEWATER, N.J., April 28, 2022 (GLOBE NEWSWIRE) — Nevakar Injectables Inc. (“Nevakar”), a wholly owned…
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Vistin Pharma ASA: Notice of Annual General Meeting
Oslo, Norway, 28 April 2020 Vistin Pharma ASA (OSE: VISTIN), please find attached the call…
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING…
ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
TORONTO, Ontario and CAMBRIDGE, MA, April 28, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX:…
Ocuphire Completes Last Clinical Trial Supporting the Planned 2022 NDA Submission with the Announcement of Positive Results from MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis
Nyxol Demonstrated a Favorable Safety Profile and Rapidly Reversed Dilated Eyes in Pediatric Subjects 3…